ZYGK1 / Zydus Lifesci - LARVOL DELTA

Evaluation of Repeat Dose Toxicity and Embryo-Fetal Developmental Toxicity of Novel Glucokinase Activator ZYGK1 in Wistar Rats. (PubMed, Int J Toxicol) - "Treatment from GD 6 to 15 caused no significant fetal abnormalities, except incidental fetal skeleton anomalies. Thus, ZYGK1 may lead to maternal hypoglycemia, but no significant developmental toxicity was observed."

Journal • Preclinical • Hypoglycemia

Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models. (PubMed, J Diabetes Complications) - "ZYGK1 appears to be a potential therapeutic option for the treatment of type 2 diabetes owing to its action in the liver and pancreas, and in conditions resistant to sulfonylurea therapy."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

"E*TRADE Wins Top Spot for Options Trading, Trader App, and Web Trading Platform by https://t.co/NjrmJOwoyK https://t.co/bf9FzyGK1B" (@NewsFromBW)